Literature DB >> 14966788

Changes in myocardial gene expression associated with beta-blocker therapy in patients with chronic heart failure.

Yoshio Yasumura1, Katsuya Takemura, Aiji Sakamoto, Masafumi Kitakaze, Kunio Miyatake.   

Abstract

BACKGROUND: The left ventricular functional recovery by beta-blocker therapy is now attributed to time-dependent biologic effects on cardiomyocytes. METHODS AND
RESULTS: To elucidate the cellular mechanism of these biologic effects, we treated 9 patients with dilated cardiomyopathy for 4 months with beta-blockers and examined the gene expressions linked to an improvement of left ventricular ejection fraction (EF). Gene expressions of the biopsied right ventricular endomyocardium were assessed by real-time reverse transcription-polymerase chain reaction. A decrease in beta-myosin heavy chain (1.23+/-0.49 versus 0.86+/-0.45, P<.05) was observed 4 months after the administration of beta-blockers. The expression levels of both sarcoplasmic reticulum Ca(2+) ATPase (SERCA) (0.80+/-0.28 versus 1.39+/-0.44, P<.01) and phospholamban (PLB) (0.49+/-0.08 versus 0.88+/-0.34, P<.05) increased, whereas the expression levels of Na(+)-Ca(2+) exchanger (NCX), beta-adrenoreceptor kinase 1, and ryanodine receptor 2 were unchanged. The SERCA/NCX ratio (0.68+/-0.14 versus 0.96+/-0.33, P<.05) also increased. The increase in SERCA mRNA expression correlated with the degree of changes in EF (%deltaEF) (r=0.679, P<.05), and none of changes in these genes expression correlated with changes in the plasma brain natriuretic peptide concentration.
CONCLUSIONS: The functional recovery resulting from beta-blockers may be associated with the restoration of the unfavorable gene expression that controls Ca(2+) handlings in the failing heart.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14966788     DOI: 10.1016/s1071-9164(03)00581-5

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  11 in total

Review 1.  Ventriculovascular coupling in systolic and diastolic heart failure.

Authors:  Justin M Fox; Mathew S Maurer
Journal:  Curr Heart Fail Rep       Date:  2005-12

2.  Ventriculovascular coupling in systolic and diastolic heart failure.

Authors:  Justin M Fox; Mathew S Maurer
Journal:  Curr Cardiol Rep       Date:  2006-05       Impact factor: 2.931

3.  Therapeutic Molecular Phenotype of β-Blocker-Associated Reverse-Remodeling in Nonischemic Dilated Cardiomyopathy.

Authors:  David P Kao; Brian D Lowes; Edward M Gilbert; Wayne Minobe; L Elaine Epperson; Leslie K Meyer; Debra A Ferguson; Ann Kirkpatrick Volkman; Ronald Zolty; C Douglas Borg; Robert A Quaife; Michael R Bristow
Journal:  Circ Cardiovasc Genet       Date:  2015-01-30

4.  Fibrosis, not cell size, delineates beta-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo.

Authors:  Kumar Pandya; Hyung-Suk Kim; Oliver Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-26       Impact factor: 11.205

5.  Identification of a novel aldose reductase-like gene upregulated in the failing heart of cardiomyopathic hamster.

Authors:  Aiji Sakamoto; Yuka Sugamoto
Journal:  Mol Cell Biochem       Date:  2011-03-27       Impact factor: 3.396

6.  Changes in collagen metabolism account for ventricular functional recovery following beta-blocker therapy in patients with chronic heart failure.

Authors:  Miho Fukui; Akiko Goda; Kazuo Komamura; Ayumi Nakabo; Mitsuru Masaki; Chikako Yoshida; Shinichi Hirotani; Masaaki Lee-Kawabata; Takeshi Tsujino; Toshiaki Mano; Tohru Masuyama
Journal:  Heart Vessels       Date:  2014-10-29       Impact factor: 2.037

7.  TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling.

Authors:  Koichiro Kuwahara; Yanggan Wang; John McAnally; James A Richardson; Rhonda Bassel-Duby; Joseph A Hill; Eric N Olson
Journal:  J Clin Invest       Date:  2006-11-09       Impact factor: 14.808

8.  Effects of treatment with a 5-HT4 receptor antagonist in heart failure.

Authors:  J A K Birkeland; I Sjaastad; T Brattelid; E Qvigstad; E R Moberg; K A Krobert; R Bjørnerheim; T Skomedal; O M Sejersted; J-B Osnes; F O Levy
Journal:  Br J Pharmacol       Date:  2006-12-11       Impact factor: 8.739

9.  MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice.

Authors:  Thomas E Callis; Kumar Pandya; Hee Young Seok; Ru-Hang Tang; Mariko Tatsuguchi; Zhan-Peng Huang; Jian-Fu Chen; Zhongliang Deng; Bronwyn Gunn; Janelle Shumate; Monte S Willis; Craig H Selzman; Da-Zhi Wang
Journal:  J Clin Invest       Date:  2009-08-10       Impact factor: 14.808

10.  Decreased beta-adrenergic responsiveness following hypertrophy occurs only in cardiomyocytes that also re-express beta-myosin heavy chain.

Authors:  Kumar Pandya; Kristine Porter; Howard A Rockman; Oliver Smithies
Journal:  Eur J Heart Fail       Date:  2009-07       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.